No­var­tis is keep­ing JULI­ET in hid­ing, but the FDA takes a peek and hands over a ‘break­through’ ti­tle

There’s been con­sid­er­able spec­u­la­tion of late about the da­ta No­var­tis has col­lect­ed from its JULI­ET study in­volv­ing its close­ly-watched CAR-T drug. The phar­ma gi­ant isn’t the best at com­mu­ni­cat­ing with the out­side world and won’t say what it has seen so far or when ex­act­ly it will be put on dis­play. But they have qui­et­ly giv­en the FDA a peek, and reg­u­la­tors seem im­pressed.

In fact, the FDA has now hand­ed over their break­through ther­a­py des­ig­na­tion for CTL019 as a new ther­a­py for dif­fuse large B-cell lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Associate

Alexandria Real Estate Equities

San Diego, CA, USA